875 related articles for article (PubMed ID: 22206794)
1. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
Chen D; Lal R; Zomorodi K; Atluri H; Ho J; Luo W; Tovera J; Bonzo D; Cundy K
Clin Ther; 2012 Feb; 34(2):351-362.e3. PubMed ID: 22325733
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.
Lal R; Sukbuntherng J; Luo W; Tovera J; Lassauzet ML; Cundy KC
J Clin Pharmacol; 2013 Jan; 53(1):29-40. PubMed ID: 23400741
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
Gordi T; Hou E; Kasichayanula S; Berner B
Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
[TBL] [Abstract][Full Text] [Related]
6. Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome.
Merlino G; Serafini A; Young JJ; Robiony F; Gigli GL; Valente M
Curr Opin Investig Drugs; 2009 Jan; 10(1):91-102. PubMed ID: 19127491
[TBL] [Abstract][Full Text] [Related]
7. The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil.
Lal R; Sukbuntherng J; Luo W; Huff FJ; Zou J; Cundy KC
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):120-8. PubMed ID: 20137764
[TBL] [Abstract][Full Text] [Related]
8. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison.
Chen C; Upward J; Arumugham T; Stier B; Davy M
Clin Ther; 2015 Feb; 37(2):349-57. PubMed ID: 25467190
[TBL] [Abstract][Full Text] [Related]
9. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate.
Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR
J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
11. Gabapentin enacarbil for treatment of restless legs syndrome in adults.
Hayes WJ; Lemon MD; Farver DK
Ann Pharmacother; 2012 Feb; 46(2):229-39. PubMed ID: 22298601
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome.
Lal R; Ellenbogen A; Chen D; Zomorodi K; Atluri H; Luo W; Tovera J; Hurt J; Bonzo D; Lassauzet ML; Vu A; Cundy KC
Clin Neuropharmacol; 2012; 35(4):165-73. PubMed ID: 22664749
[TBL] [Abstract][Full Text] [Related]
13. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
Vollmer T; Henney HR
Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of repaglinide in subjects with renal impairment.
Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P
Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
17. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
18. Gabapentin enacarbil in restless legs syndrome.
Merlino G; Serafini A; Lorenzut S; Sommaro M; Gigli GL; Valente M
Drugs Today (Barc); 2010 Jan; 46(1):3-11. PubMed ID: 20200691
[TBL] [Abstract][Full Text] [Related]
19. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
